For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced that it has initiated the first of 5 new trial sites in Taiwan as it progresses the phase 2 clinical trial of its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis. These latest centres join 11 active sites across Australia and South Korea with a further 4 centres in the US expected to come on stream in coming months.
Pharmaxis CEO Gary Phillips said, “This planned initiation of new trial sites in Taiwan will bring the total number of active sites to 16. The study is making pleasing progress as it builds to a recruitment target of 24 patients. This latest expansion of sites is part of a focused effort by the company to bring patients into the trial and deliver results by the year end.”
Mr Phillips added, “We know from the earlier dose escalation study that PXS-5505 will fully block the LOX enzymes that play a fundamental part in the bone marrow fibrosis that characterises myelofibrosis, giving hope that the drug can modify the course of the disease. The good tolerability profile, which is a key differentiator from current standard of care, was first demonstrated in healthy volunteers and then backed up by myelofibrosis patients on 1 month of therapy in the dose escalation study. I am pleased to report that we now have experience with patients who have had 3 or more months of therapy on PXS-5505 and that the good tolerability profile is being maintained.”Read full media release - pdf
- Collaboration with research team led by Professor Fiona Wood AM doses first patients in trial of 50 patients with established scars
- 3-month placebo-controlled study to report safety and tolerability endpoints as well as measures of scar structure and appearance in 2H 2022
- PXS-6302 is a first in class topical inhibitor of the lysyl oxidase enzymes that are involved in formation and maintenance of scars; a potential breakthrough treatment for patients with problematic scars in a market estimated at US$3.5 billion per year
Pharmaxis Ltd (ASX: PXS) will release its Quarterly Shareholder Update on the morning of 31 January 2022.
Investors and analysts are invited to participate in a virtual investor briefing by the Company’s chief executive officer Mr Gary Phillips at 11.00am AET on Monday 31 January 2022.
The event will consist of a short presentation of the Company’s progress over the past quarter and future plans followed by a Q&A session from attendees.
The event is free to attend, and investors should register in advance using the following registration link:
Upon registration, instructions for joining the session will be sent via email.
To ensure as many questions as possible can be responded to in the allotted time, Pharmaxis welcomes investors to pre-submit questions by emailing them to: firstname.lastname@example.orgRead full media release - pdf